You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Metformin and risk of hepatocellular carcinoma: are statins the missing link?
  1. Siddharth Singh1,
  2. Preet Paul Singh2
  1. 1 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
  2. 2 Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to
    Dr Siddharth Singh, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA; singh.siddharth2{at}mayo.edu

http://dx.doi.org/10.1136/gutjnl-2012-304232

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest, the recent article titled ‘Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies’ by Chen and colleagues published online in July in Gut.1 In this large, population-based, case-control study using the Taiwanese National Health Insurance Research Database, they reported that in patients with diabetes mellitus (DM), metformin use is associated with a decrease in the risk of hepatocellular cancer (HCC) in a dose- and duration-dependent manner. Metformin users had a 21% lower risk of HCC on multivariate stratified analysis, after adjusting for potential confounders (age, gender, hepatitis B, hepatitis C, liver cirrhosis, DM duration and antidiabetic therapy). …

    View Full Text

    Footnotes

    • Contributors Both authors have contributed equally to the drafting of this letter.

    • Disclaimers None.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles